BIOMARKER:

CD163 overexpression

Entrez ID:

Related biomarkers:

‹

›

CD163 overexpression CD163 overexpression	Hodgkin Lymphoma HL	CD163 overexpression CD163 overexpression	Hodgkin Lymphoma HL	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
CD163 overexpression CD163 overexpression	Solid Tumor Solid Tumor	CD163 overexpression CD163 overexpression	Solid Tumor Solid Tumor	avelumab + eftilagimod alpha Sensitive: C3 – Early Trials	avelumab + eftilagimod alpha Sensitive: C3 – Early Trials
CD163 overexpression CD163 overexpression	Solid Tumor Solid Tumor	CD163 overexpression CD163 overexpression	Solid Tumor Solid Tumor	eftilagimod alpha Sensitive: C3 – Early Trials	eftilagimod alpha Sensitive: C3 – Early Trials